Characteristics and outcomes of Italian patients from the observational, multicentre, hypopituitary control and complications study (HypoCCS) according to tertiles of growth hormone peak concentration following stimulation testing at study entry

2015 ◽  
Vol 83 (4) ◽  
pp. 527-535 ◽  
Author(s):  
Marco Losa ◽  
Paolo Beck-Peccoz ◽  
Gianluca Aimaretti ◽  
Carolina Di Somma ◽  
Maria Rosaria Ambrosio ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Peak Concentration ◽  
Study Entry ◽  
Growth Hormone Peak

EFFECT OF GROWTH HORMONE-RELEASING FACTOR (1–44)NH2 ADMINISTRATION ON SOMATOTROPIN IN PIGS

1990 ◽  
Vol 70 (3) ◽  
pp. 785-793 ◽  
Author(s):  
J. L. JOHNSON ◽  
M. T. COFFEY ◽  
K. L. ESBENSHADE ◽  
B. R. SCHRICKER
Keyword(s):  
Growth Hormone ◽  
Dose Response ◽  
Peak Concentration ◽  
Single Injection ◽  
Latin Square ◽  
Human Growth ◽  
Blood Samples ◽  
Growth Hormone Releasing Factor ◽  
The Relationship ◽  
Related Increase

Two experiments were conducted to examine the dose response and optimum pattern of subcutaneous (s.c.) administration of human growth hormone-releasing factor [hGRF (1–44)NH2]on serum somatotropin (ST) in barrows. In exp. 1, 10 barrows (79.9 ± 3.3 kg) were used in a replicated 5 × 5 Latin square and blood samples were collected for 300 min from a single injection of hGRF. Injecting 0, 1, 10, 40 or 100 μg hGRF kg−1 resulted in dose related increase (P < 0.01) in peak concentrations of pST (3.93, 4.41, 10.61, 16.01 and 23.56 ng mL−1), and area under the ST response curve (AUC) (565.4, 546.2, 757.5, 1048.0 and 1314.0 ng min mL−1, respectively). The 40 μg kg−1 dose resulted in a higher (P < 0.05) peak pST and AUC than 0 or 1 μg hGRF kg−1. Peak concentration and AUC were greater (P < 0.05) for the 100 μg hGRF kg−1 dose compared with the 0, 1 and 10 μg hGRF kg−1 doses, but there was no difference between the 40 and 100 μg kg−1 doses. In exp. 2, eight barrows (85.4 ± 8.0 kg) were used in a replicated 4 × 4 Latin square to examine the relationship between pattern of hGRF administration and serum ST. Blood samples were collected −15, 0 and 15 min from initiation of administration and then hourly for 24 h. Treatments were designed to deliver 160 μg hGRF kg−1 every 24 h and were administered as 40 μg kg−1 injected four times daily, 80 μg kg−1 injected twice daily or by continuous s.c. infusion. There was no difference (P > 0.10) between treatments for peak ST concentration, AUC or area above the ST baseline. These data indicated a dose response to s.c. hGRF injections and ST in barrows. Further, ST response was not altered by the pattern of s.c. administration when barrows received 160 μg hGRF kg−1 daily by either 4 or 2 discrete injections or by continuous infusion. Key words: Swine, somatotropin, growth hormone-releasing factor

scholarly journals O Papel dos Testes de Estimulação Farmacológica no Diagnóstico da Deficiência de Hormona do Crescimento em Crianças e Adolescentes

2014 ◽  
Vol 27 (5) ◽  
pp. 587
Author(s):  
Jean-Pierre Gonçalves ◽  
Filipa Correia ◽  
Helena Cardoso ◽  
Teresa Borges ◽  
Maria João Oliveira
Keyword(s):  
Growth Hormone ◽  
Logistic Regression ◽  
Growth Hormone Deficiency ◽  
Hormone Deficiency ◽  
Growth Disorders ◽  
Z Score ◽  
Hormone Stimulation ◽  
Growth Hormone Peak ◽  
Pharmacological Stimulation ◽  
Stimulation Tests

<p><strong>Introduction:</strong> The incidence of short stature associated with growth hormone deficiency has been estimated to be about 1:4000 to 1:10000. It is the main indication for treatment with recombinant growth hormone.<br /><strong>Objectives:</strong> The aims of the study were to evaluate the results of growth hormone stimulation tests and identify the growth hormone deficiency predictors.<br /><strong>Material and Methods:</strong> A cross-sectional, analytical and observational study was conducted. We studied all the children and adolescents submitted to growth hormone pharmacological stimulation tests between January 2008 and May 2012. Growth hormone deficiency diagnosis was confirmed by two negatives growth hormone stimulation tests (growth hormone peak &lt; 7 ng/ml). The statistical analysis was performed using student t-test, chi-square, Pearson correlation and logistic regression. Statistical significance determined at the 5% level (p ≤ 0.05).<br /><strong>Results:</strong> Pharmacological stimulation tests were performed in 89 patients, with a median age of 10 [3-17] years. Clonidine (n = 85) and insulin tolerance test (n = 4) were the first growth hormone stimulation tests performed. Growth hormone deficiency was confirmed in 22 cases. In cases with two growth hormone stimulation tests, the growth hormone peak showed a moderate correlation (r = 0.593, p = 0.01). In logistic regression model height (z-score) and the growth hormone peak in first stimulation test were predictors of growth hormone deficiency diagnosis (each one unit increase in z-score decrease the growth hormone deficiency probability).<br /><strong>Discussion:</strong> Measurement of IGF-1 cannot be used in diagnosing growth hormone deficiency.<br /><strong>Conclusion:</strong> Auxological criteria associated with a positive test seems to be a reliable diagnostic tool for growth hormone deficiency.</p><p><br /><strong>Keywords:</strong> Growth Disorders; Human Growth Hormone/blood.</p>

scholarly journals Growth hormone peak modifies the effect of BMI on increased systolic blood pressure in children with short stature

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Yanying Li ◽  
Yanhong Zhang ◽  
Mei Zhang ◽  
Wanling Yang ◽  
Baolan Ji ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Growth Hormone ◽  
Systolic Blood Pressure ◽  
Short Stature ◽  
Growth Hormone Peak

Inverse control of growth hormone and prolactin secretion in clonidine-stimulated dairy cattle

1995 ◽  
Vol 146 (2) ◽  
pp. 271-277 ◽  
Author(s):  
V Borromeo ◽  
A Berrini ◽  
F Möller ◽  
C Secchi
Keyword(s):  
Growth Hormone ◽  
Dairy Cattle ◽  
Dairy Cows ◽  
Peak Concentration ◽  
Plasma Insulin ◽  
Prolactin Secretion ◽  
Inverse Control ◽  
Significant Difference ◽  
Plasma Gh ◽  
Plasma Prl

Abstract Clonidine is a specific α-2-adrenoreceptor agonist that stimulates growth hormone (GH) release in animals and humans. This drug was used to study the GH and prolactin (PRL) secretory response in dairy cows and heifers. An i.v. infusion of 10 μg/kg body weight induced GH release to a peak concentration after 30–60 min, while 2 μg/kg had no effect on GH secretory patterns. Plasma PRL decreased significantly (P<0·01) starting 15–60 min after both doses of clonidine, this effect lasting up to 6 h. Clonidine significantly lowered plasma insulin (P<0·01) and raised plasma glucose (P<0·01). The changes in plasma GH, PRL, insulin and glucose differed significantly between doses, the 10 μg/kg dose being more effective (P<0·01). The results of our investigation in dairy cattle provide evidence of (i) an increase in GH release after 10 μg/kg clonidine; (ii) a concomitant decrease in PRL secretion, hence GH and PRL secretion in cattle appear inversely controlled; (iii) a significant difference between the effects of the 2 and 10 μg/kg doses and (iv) no relationship between the changes in plasma GH and PRL after clonidine and plasma hormone levels before treatment. Journal of Endocrinology (1995) 146, 271–277

Sign in / Sign up

Export Citation Format

Share Document